WO2001077178A2 - Compositions and methods for detection of von willebrand's disease - Google Patents
Compositions and methods for detection of von willebrand's disease Download PDFInfo
- Publication number
- WO2001077178A2 WO2001077178A2 PCT/US2001/011487 US0111487W WO0177178A2 WO 2001077178 A2 WO2001077178 A2 WO 2001077178A2 US 0111487 W US0111487 W US 0111487W WO 0177178 A2 WO0177178 A2 WO 0177178A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- nucleic acid
- von willebrand
- nucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates generally to compositions and methods for detection of von Willebrand' s disease.
- the present invention relates to the use of nucleic acids and polypeptides associated with the von Willebrand's Factor gene in the diagnosis, treatment and prevention of von Willebrand's disease in dogs.
- Von Willebrand's disease is the most common bleeding disorder in both humans and dogs and may vary in severity due to the of levels of von Willebrand's factor that results from a quantitative or qualitative defect in von Willebrand's Factor (vWF) (Ginsburg, D. et al., Blood 79:2507-2519 (1992); Ruggeri, Z. M., et al., FASEBJ7:308-316 (1993); Dodds, W. J., Mod Vet Pract681-686 (1984); Johnson, G. S. et al., JAVMA 176:1261-1263 (1988); Brooks, M., Probl In Vet Med 4:636-646 (1992)).
- vWF von Willebrand's Factor
- vWF functions to stabilize Factor VIII (hemophilic factor A), and aids in the adhesion of platelets to the subendothelium, allowing them to provide hemostasis more effectively.
- Type 1 vWD appears to be caused by a reduced level of vWF and is generally inherited in a dominant, incompletely penetrant fashion. It is considered to be a mild form of the disease, and is the most common form of vWD found in most mammals, but can still cause serious bleeding problems.
- Type 2 vWD patients may have essentially normal levels of vWF, but the factor does not function properly. (Ruggeri, Z.
- Type 2 is inherited in a dominant fashion and is not common in dogs (Turrentine, M. A., et al., Vet Clin North Am Small Anim Pract 18:275 (1988)).
- Type 3 vWD the most severe form of the disease, is inherited as an autoso al recessive trait and affected individuals have no detectable vWF in their blood. This results in serious bleeding episodes that require transfusions of blood or cryoprecipitate. Heterozygotes have moderately reduced factor concentrations, but can clot normally. Because homozygotes have no detectable vWF they have a severe bleeding disorder.
- a more useful test would be a direct DNA test using sequences from the canine vWD gene. Since purebred dog populations are highly inbred, most disease causing mutations are the result of a founder effect, and are therefore conserved within a given breed. Therefore, it would be desirable to provide specific mutations for specific breeds. Furthermore it would be desirable to provide a method for determining the genotype of an animal, so that carriers of the mutation could be bred to those who are clear of the mutation, and therefore no affected offspring would be produced.
- the invention involves an isolated nucleic acid molecule having a nucleotide sequence encoding a mutated canine von Willebrand's Factor polypeptide which causes canine von Willebrand's disease.
- the nucleotide sequence of this nucleic acid sequence is capable of hybridizing under high stringency conditions to the complementary sequence of the sequence of SEQ ID NO: 1 , having a mutation at nucleotide 172, or SEQ ID NO:2, having a mutation at nucleotide 384.
- the invention also involves a vector containing the nucleic acid molecule.
- the invention is concerned with a cell containing such a vector.
- the mutation at nucleotide 172 of SEQ ID NO:l is a nucleic acid substitution.
- nucleic acid substitution is meant that the nucleotide present in the normal allele is substituted for a different nucleotide in the mutated allele.
- the tenn “normal allele” refers to the nucleic acid sequence encoding the nonmutated canine von Willebrand's Factor polypeptide.
- mutant allele refers to the nucleic acid sequence encoding the mutated canine von Willebrand's Factor polypeptide.
- the "G" present at position 172 of the normal allele of SEQ ID NO: 1 is an "A" in the mutant allele.
- the mutation at nucleotide 384 of SEQ ID NO:l is a nucleic acid deletion mutation.
- nucleic acid deletion mutation is meant that at least one of the nucleotides present in the normal allele is deleted in the mutant allele.
- the "T" at position 384 of SEQ ID NO:2 is deleted.
- the invention in another aspect, involves a method of detecting a canine von Willebrand's Factor gene in a sample.
- This method involves the steps of contacting the sample with an oligonucleotide comprising at least 10 contiguous nucleotides derived from the nucleic acid sequences of SEQ ID NOS: 1 or 2, or complements thereof, and capable of specifically hybridizing with the canine von Willebrand's Factor gene, under conditions favorable for hybridization of the oligonucleotide to any complementary sequence of nucleic acid in the sample and detecting the hybridization, thereby detecting a canine von Willebrand's Factor gene.
- this method further involves the step of quantifying the hybridization of the oligonucleotide to the complementary sequence.
- SEQ ID NO:l has a nucleic acid substitution at nucleotide 172.
- SEQ ID NO:2 has a nucleic acid deletion at nucleotide 384.
- the invention involves an assay kit for screening for a canine von Willebrand's Factor gene.
- This kit contains an oligonucleotide having at least 10 contiguous nucleotides of the nucleic acid sequences of SEQ ID NOS : 1 or 2, or complements thereof, and capable of hybridizing with the nucleotide sequence encoding canine von Willebrand's Factor; reagents for hybridization of the oligonucleotide to a complementary nucleic acid sequence; and container means for the oligonucleotide and the reagents.
- SEQ ID NO:l has a nucleic acid substitution at nucleotide 172 or SEQ ID NO:2 has a nucleic acid deletion at nucleotide 384.
- the invention involves an assay kit for screening for a canine von Willebrand's Factor gene.
- This kit contains an oligonucleotide having contiguous nucleotides of the nucleic acid sequence that is complementary to the sequence of SEQ ID NO:l having a mutation at nucleotide 172 and capable of specifically hybridizing to the complementary nucleotide sequence; reagents for the hybridization of the oligonucleotide to a complementary nucleic acid sequence; and container means for the oligonucleotide and the reagents.
- the mutation in SEQ ID NO:l is a nucleic acid substitution.
- the invention involves an assay kit for screening for a canine von Willebrand's Factor gene.
- This kit contains an oligonucleotide having contiguous nucleotides of the nucleic acid sequence that is complementary to the sequence of SEQ ID NO:2 having a mutation at nucleotide 384 and capable of specifically hybridizing to the complementary nucleotide sequence; reagents for the hybridization of the oligonucleotide to a complementary nucleic acid sequence; and container means for the oligonucleotide and the reagents.
- the mutation in SEQ ID NO:2 is a nucleic acid deletion mutation.
- the invention is concerned with methods for detecting a mutated canine von Willebrand's Factor gene in a canine DNA sample.
- this method involves the amplification of the DNA sample by polymerase chain reaction to produce polymerase chain reaction products, wherein the polymerase chain reaction uses primers that produce a restriction site in a normal allele but not in a mutant allele, wherein the mutation in the mutant allele is a substitution at nucleotide 172 of the nucleotide sequence encoding canine von Willebrand's Factor polypeptide, wherein the nucleotide sequence is capable of hybridizing under high stringency conditions to the complementary sequence of the sequence of SEQ LO NO.l; digesting the polymerase chain reaction products with a restriction enzyme specific to the restriction site of the primer to produce DNA fragments; and detecting the DNA fragments thereby detecting a mutated canine von Willebrand's Factor gene.
- the DNA fragments can be detected by, e.g., gel electrophoresis.
- the primers may alternatively be the primers of SEQ ID NO:3 and SEQ ID NO:4 or the primers of SEQ ID NO: 3 and SEQ ID NO: 9.
- the restriction enzymes may be either Taq l orHp l.
- this method involves the amplification of the DNA sample by polymerase chain reaction to produce polymerase chain reaction products, wherein the polymerase chain reaction uses primers that are complementary to sequences of the introns flanking the exon, wherein the exon of the mutant allele has a deletion at nucleotide 384 of the nucleotide sequence encoding canine von Willebrand's Factor polypeptide, wherein the nucleotide sequence is capable of hybridizing under high stringency conditions to the complementary sequence of the sequence of SEQ ID NO:2; digesting the polymerase chain reaction products with a restriction enzyme specific to the restriction site of the mutant allele to produce DNA fragments; and detecting the DNA fragments thereby detecting a mutated canine von Willebrand's Factor gene.
- the DNA fragments can be detected by, e.g., gel electrophoresis.
- the primers may alternatively comprise the sequence of SEQ ID NO:5 and SEQ ID NO:6 or the sequence of SEQ ID NO:7 and SEQ ID NO:8.
- the restriction enzyme is Mwo I.
- the invention involves an oligonucleotide probe capable of detecting a mutation associated with canine von Willebrand's disease, wherein the mutation is a base substitution at nucleotide 172 of the nucleotide sequence encoding canine von Willebrand's Factor polypeptide, wherein the nucleotide sequence is capable of hybridizing under high stringency conditions to the complementary sequence of SEQ ID NO: 1.
- the substitution at nucleotide 172 is adenine for guanine.
- FIG. 1. is the nucleic acid sequence of part of intron 42, exon 43, and part of intron 43 of the canine von Willebrand's Factor of the present invention (SEQ ID NO: 1). Intronic sequences are shown in lower case and exon 43 is shown in capital letters. Splice donor and acceptor sequences are underlined. The location of the nucleic acid substitution is shown in bold.
- FIG. 2 is a comparison of the genomic region encompassing part of intron 42, exon 43, and part of intron 43 (SEQ ID NO:l) with the human von Willebrand's gene located on human chromosome 12 (BAC clone from GenBank). Splice donor and acceptor sequences are underlined.
- FIG. 3 A illustrates the results of a method of the present invention used to detect mutations in the von Willebrand's gene found in Doberman pinschers, Manchester terriers, Pembroke Welsh corgi's, and Poodles (all three varieties).
- the forward and reverse primers from introns 42 and 43 are shown (SEQ ID NO: 3 and 4). Splice donor and acceptor sequences are underlined. The nucleic acid substitution is shown in bold,
- FIG. 3B shows the result of amplification with the diagnostic primer (SEQ ID NO: 5) of the wild type and mutant allele, resulting in a Taq 1 restriction site in the wild type, but not the mutant allele.
- FIG.4 is a photograph of an agarose gel showing representative results of the PCR-based diagnostic test for type I von Willebrand's disease as occurs in Doberman pinschers, Manchester terriers, Bernese mountaindogs, Pembroke Welsh corgi's, and Poodles (all three varieties).
- Lane 1 shows a 100 base pair ladder for size markers.
- Lane 2 shows Taq I digested DNA of an animal that is homozygous wild type.
- Lane 3 shows Taq I digested DNA of an animal that is heterozygous wild type (carrier ol the mutation).
- Lane 4 shows Taq I digested DNA of an animal that is homozygous mutant (affected with von Willebrand's disease).
- FIG.5 is the nucleic acid sequence of part of intron 6, exon 7, and part of intron 7 for the canine von Willebrand's Factor of the present invention (SEQ ID NO: 2). Intronic sequences are given in lower case and exon 7 is shown in upper case. Primer sequences used for amplification (SEQ ID NO: 5 and 6) are indicated by the clear boxes and the naturally occurring Mwo 1 restriction site is indicated by the shaded box.
- FIG. 6 is a photograph of an agarose gel showing representative results of the PCR-based diagnostic test for type III von Willebrand's disease as occurs in Shetland sheepdogs.
- Lane 1 shows a 100 base pair ladder for size markers.
- Lane 2 shows Mwo 1 digested DNA of an animal that is homozygous wild type.
- Lane 3 shows Mwo 1 digested DNA of an animal that is heterozygous wild type (carrier of the mutation).
- Genomic DNA comprising part of intron 42, all of exon 43, and part of intron 43 from the canine von Willebrand's Factor Gene is set forth in FIG. 1 and SEQ ID NO: 1.
- Genomic DNA comprising part of intron 6, all of exon 7, and part of intron 7 from the canine von Willebrand's Factor gene is set forth in FIG 5 and SEQ ID NO:2.
- the mutation of the normal vWF gene which causes von Willebrand's Disease (vWD) in Shetland Sheepdogs, a single base deletion in exon 7 is provided.
- a splice junction mutation at the last nucleotide of exon 43 of the canine von Willebrand's Factor gene which causes vWD in Doberman pinschers, Manchester terriers and Poodles, and Pembroke welsh corgi's.
- the nucleic acid sequences of the present invention may be used in methods for detecting homozygous (mutant or wild type alleles) and heterozygous carriers of the defective vWF gene.
- DNA samples are first collected by relatively non-invasive techniques that do not require penetration into the tissues of the animal. Withdrawing buccal cells via cheek swabs or withdrawing blood samples are two common methods that could be used to obtain DNA (Richards, B. et al., "Multiplex PCR Amplification from the CFTR Gene Using DNA Prepared from Buccal Bushes/Swabs," Human Molecular Genetics 2: 159-163 (1992)). Following isolation of the DNA by standard techniques, PCR is perfo ⁇ ned on the DNA extracted from these biological samples utilizing primers designed to produce enzyme restriction sites on those DNA samples at with the normal or mutant allele sequence.
- LAR ligation amplification reaction technology
- LAR is a method analogous to PCR for DNA amplification wherein ligases are employed for elongation in place of polymerases used for PCR.
- Other methods for allele discrimination in the canine von Willebrand's factor gene known to those skilled in the art include methods that use allele specific oligonucleotide hybridization, such as molecular beacons (Tyagi S, Kramer FR, "Molecular beacons: probes that fluoresce upon hybridization," Nat Biotechnol 1996 Mar;14(3):303-8).
- the present invention provides breeders and dog owners with an accurate, definitive test that will provide them with the genotype of their animals with respect to von
- the information obtained from these genetic tests can, in turn, be used to completely eliminate von Willebrand's disease from breeding populations, by breeding animals that carry the mutation to those that do not have the mutation, and choosing a clear animal for the next generation of breeding. Animals that are currently tested using a protein- based ELISA assay, are often misdiagnosed, as the variability of results with this test results in ambiguity between animals that are carriers and those that are clear.
- the present invention provides unambiguous diagnosis of von Willebrand's disease in canines as described in the Specific Examples, and methods of the present invention.
- nucleic acid refers to a linear array of nucleotides and nucleosides, such as genomic DNA, cDNA, and DNA prepared by partial or total chemical synthesis from nucleotides.
- nucleic acid may be transcribed and translated into the desired polypeptide.
- Polypeptide refers to amino acid sequences which comprise both full-length proteins and fragments thereof.
- “Mutation” as referred to herein includes any alteration in a nucleic acid sequence including, but not limited to, deletions, substitutions and additions.
- hybridizing under high stringency conditions means annealing a strand of DNA complementary to the DNA of interest under highly stringent conditions.
- “capable of hybridizing under low stringency conditions” refers to annealing a strand of DNA complementary to the DNA of interest under low stringency conditions.
- hybridizing under either high or low stringency conditions would involve hybridizing a nucleic acid sequence (e.g., the complementary sequence to SEQ ID NO: 1 or portion thereof), with a second target nucleic acid sequence.
- “High stringency conditions” for the annealing process may involve, for example, high temperature and/or low salt content, which disfavor hydrogen bonding contacts among mismatched base pairs.
- Low stringency conditions would involve lower temperature, and/or higher salt concentration than that of high stringency conditions. Such conditions allow for two DNA strands to anneal if substantial, though not nearly complete complementarity exists between the two strands, as is the case among DNA strands that code for the same protein but differ in sequence due to the degeneracy of the genetic code.
- the salt concentration in the wash step can be selected from a low stringency of about 2xSSC at 50°C to a high stringency of about 0.2xSSC at 50°C.
- the temperature in the wash step can be increased from low stringency at room temperature, about 22°C, to high stringency conditions, at about 65°C.
- Other stringency parameters are described in Maniatis, T., et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring N.Y., (1982), at pp. 387-389; see also Sambrook J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Volume 2, Cold Spring Harbor Laboratory Press, Cold Spring, N.Y. at pp. 8.46-8.47 (1989). The invention will be further described in the following examples which do not limit the scope of the invention described in the claims.
- Type 1 von Willebrand's disease is not severe. Affected individuals do have some ability to clot, unlike the more severe Type 3 form of the disease, in which individuals do not produce any vWF protein. As such, one would predict that the mutation for type 1 might be located towards the 3' end of the gene. Numerous fragments from the 3' end of the vWF gene including exons 45-47 (data not shown), and an inverse PCR product from exon 43 were cloned and sequenced. Inverse PCR is a technique to obtain DNA sequencing data.
- sequences of the primers used were: intronic 5' to the mutation (sense primer, forward primer), 5'-GCATGGAAATCTTGTGTTTGTAG-3' (SEQ ID NO:3); and intronic 3' to the mutation (antisense primer, reverse primer), 5'- TGCCCTGCCCCTCTGCTCCCCTTAT-3* (SEQ ID NO : 4).
- Use of these primers generates a Taq I restriction enzyme site in the wild type sequence, but not the mutant sequence (Fig. 3B).
- another primer intronic 3' to the mutation (antisense primer, reverse primer), 5'-TGCCCTGCCCCTCTGCTCCCCTCAC-3' (SEQ ID NO: 9) is also contemplated. This primer generates a Hph I restriction enzyme site in the wild type sequence, but not the mutant sequence.
- PCR-Based Mutation Test PCR mutagenesis was used to create a Taq I site in the normal allele but not in the mutant allele.
- the control site is contained within the amplification products of both alleles.
- the sequences of the primers are: (sense) primer, 5'- GCATGGAAATCTTGTGTTTGTAG-3' (SEQ ID NO:3) and the diagnostic antisense primer 5 '-TGCCCTGCCCCTCTGCTCCCCTTAT-3 ' (SEQ ID NO:4).
- the cycling conditions were 94°C for two minutes followed by 35 cycles of 92°C for one minute, 58°C for one minute 30 sees., and 72°C for one minute and 30 seconds.
- the splice junction mutation at the end of exon 43 is the cause of recessive Type 1 vWD found in at least five canine breeds (Doberman pinscher, Bernese mountaindogs, Manchester terrier, Poodle, and Pembroke Welsh corgi's).
- a mutation was found in the vWF gene that appears to be responsible for most or all of the type 3 vWD found in the Sheltie breed.
- a deletion of a single "T” was found at nucleotide position of 384 of SEQ ID NO:2.
- the forward primer, intronic 5' to the mutation was 5'- actaatccaacgcactgtcgagc-3'(SEQ ID NO:5)
- the reverse primer, intronic 3' to the mutation was 5'-aaggtccaggatggtgacac-3'(SEQ ID NO: 6).
- the cycling conditions were: 94°C, 2 min, one cycle, followed by 35 cycles of 94°C,
- DNA sequences to amplify the relevant portion of the vWF gene can also be used: forward primer, intronic 5' to the mutation 5'-
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001251462A AU2001251462A1 (en) | 2000-04-07 | 2001-04-07 | Compositions and methods for detection of von willebrand's disease |
US10/088,256 US20030207272A1 (en) | 2001-04-07 | 2001-04-07 | Composition and methods for detection of von willebrand's disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19554400P | 2000-04-07 | 2000-04-07 | |
US60/195,544 | 2000-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001077178A2 true WO2001077178A2 (en) | 2001-10-18 |
WO2001077178A8 WO2001077178A8 (en) | 2002-09-12 |
Family
ID=22721806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011487 WO2001077178A2 (en) | 2000-04-07 | 2001-04-07 | Compositions and methods for detection of von willebrand's disease |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001251462A1 (en) |
WO (1) | WO2001077178A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868820A (en) * | 2017-10-26 | 2018-04-03 | 深圳深知生物科技有限公司 | Method, primer and the kit of canine multiple genetic disease examination |
-
2001
- 2001-04-07 AU AU2001251462A patent/AU2001251462A1/en not_active Abandoned
- 2001-04-07 WO PCT/US2001/011487 patent/WO2001077178A2/en active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107868820A (en) * | 2017-10-26 | 2018-04-03 | 深圳深知生物科技有限公司 | Method, primer and the kit of canine multiple genetic disease examination |
CN107868820B (en) * | 2017-10-26 | 2021-02-12 | 深圳深知生物科技有限公司 | Primer group and kit for canine multiple genetic disease screening |
Also Published As
Publication number | Publication date |
---|---|
WO2001077178A8 (en) | 2002-09-12 |
AU2001251462A1 (en) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002006529A2 (en) | Detection and treatment of polycystic kidney disease | |
US20040132021A1 (en) | Osteolevin gene polymorphisms | |
EP0961836B1 (en) | Dna encoding canine von willebrand factor and methods of use | |
CA2357758C (en) | Dna encoding canine von willebrand factor and methods of use | |
US5804388A (en) | Chromosome 9 and progressive rod-cone degeneration disease genetic markers and assays | |
GINSBURG | The von Willebrand factor gene and genetics of von Willebrand's disease | |
US6410237B1 (en) | DNA encoding canine von Willebrand factor and methods of use | |
WO2008014550A1 (en) | Markers for pigmentation | |
WO2001077178A2 (en) | Compositions and methods for detection of von willebrand's disease | |
US20030207272A1 (en) | Composition and methods for detection of von willebrand's disease | |
US6780583B1 (en) | DNA encoding canine von willebrand factor and methods of use | |
CA2852631A1 (en) | A gene and mutations thereof associated with seizure and movement disorders | |
CN106957907B (en) | Genetic test for liver copper accumulation in dogs | |
EP3412776B1 (en) | Genetic polymorphism associated with dog afibrinogenemia | |
WO2001081633A1 (en) | Association of protein kinase c zeta polymorphisms with diabetes | |
US6767707B2 (en) | DNA encoding canine von willebrand factor and methods of use | |
US7608400B2 (en) | Methods for detecting a cyclophilin B SNP associated with HERDA | |
US9157119B2 (en) | Methods for diagnosing skin diseases | |
WO2009134226A1 (en) | Canine coat color prediction | |
AU2004247896B2 (en) | Mutations in the SLC40A1 gene associated to impaired iron homeostasis | |
US7442509B2 (en) | Detecting mutations in the feline cardiac myosin binding protein C gene associated with hypertrophic cardiomyopathy in cats | |
WO1999037812A9 (en) | Single nucleotide polymorphisms of the uncoupling protein 2 (ucp2) gene | |
EP2151502A1 (en) | Genetic variations associated with feather pecking behaviour in avians | |
WO2003033734A2 (en) | Diagnostic tests for the diagnosis of copper storage disease | |
HUE025558T2 (en) | Method of determining the genotype relating to hereditary nasal parakeratosis (HNPK) and nucleic acids usable in said method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10088256 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
D17 | Declaration under article 17(2)a | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |